Status:

COMPLETED

Efficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland Tanzania

Lead Sponsor:

National Institute for Medical Research, Tanzania

Conditions:

Uncomplicated Malaria

Eligibility:

All Genders

6-10 years

Brief Summary

Following the development of drug resistance to antimalarial first line treatment of uncomplicated malaria with SP by P.falciparum in mainland Tanzania, the Ministry of Health - Tanzania, introduced A...

Detailed Description

The study was on safety and efficacy of artemether lumefantrine for the treatment of uncomplicated malaria, to be done in 8 National Malaria Control Programme sentinel sites The study was proposed to ...

Eligibility Criteria

Inclusion

  • • Patients aged 6 months-10 years.
  • mono-infection with P. falciparum detected by microscopy;
  • parasitaemia of 250 - 200,000/μl asexual forms;
  • presence of axillary temperature ≥37.5 °C or history of fever during the past 24 hours
  • ability to swallow oral medication;
  • ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
  • Informed consent from the parents or guardians of children.

Exclusion

  • presence of general danger signs in children aged 6 months-10 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1);
  • weight under 5 Kg
  • mixed or mono-infection with another Plasmodium species detected by microscopy;
  • presence of severe malnutrition (defined as a child who has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 110 mm);
  • presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
  • regular medication, which may interfere with antimalarial pharmacokinetics;
  • history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s

Key Trial Info

Start Date :

April 1 2016

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 1 2016

Estimated Enrollment :

344 Patients enrolled

Trial Details

Trial ID

NCT03387631

Start Date

April 1 2016

End Date

September 1 2016

Last Update

January 2 2018

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.